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Summary We report a Li-Fraumeni syndrome family in which we have detected a splice acceptor mutation in intron 3 of TP53. The mutation
affects one of the invariant residues at the splice acceptor site. as a result of which two aberrant transcripts are produced. A child with Wilms
tumour aged 3 years in this family was shown not to be a mutation carrier.
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Li-Fraumeni sxndrome (LFS) is a rare autosomal dominant
disorder in which there is greatly increased cancer susceptibilitN.
LFS is characterized bv bone and soft-tissue sarcomas. earlv-onset
breast cancer. brain tumours. leukaemia and childhood adreno-
cortical tumours (Li et al. 1988). and a proportion of LFS families
show germline transmission ofa mutant TP53 gene. We hav-e iden-
tified an LFS familv in which there is a number oftumours typical
ofthe syndrome. and we have screened for agermline TP53 muta-
tion. The identification of a TP53 mutation in this familv (Varlev
et al. 1997) has allowved us to exclude a number ofcancer-affected
indi' iduals in the familv from linkage to a germline TP53 muta-
tion. includinc a child Aith Wilms' tumour.
PATIENTS AND METHODS
The pedigree of family 86 is sho'a-n in Figure 1. There is a high
incidence ofcancer in the family. which conforms to the definition
ofclassic LFS (Li et al. 1988). Blood samples were obtained from
V-3 (chondroblastic osteosarcoma ofthe humerus aged 15) and his
parents. and DNA from V-3 and IV-5 Aere screened for a germ-ine
TP53 mutation by direct sequencing of all exons as described
previously (Varley et al. 1997). DNA from other family members
' as derived from blood or from paraffin-embedded normal tissue.
Three forward and two reverse primers were used to amplify
and sequence DNA from exons 3 and 4 of TP53. Reverse
transcriptase polymerase chain reaction (RT-PCR) analysis was
carried out on poly-A+ RNA extracted from lymphocytes from IV-
5 and V-3. using primers w'ithin exons 2/3 and 5 or 5/6. The exon
2/3 and exon 5/6 primers wAere designed to span tx-o exons to elim-
inate any possibility of amplifying genomic DNA in the RT-PCR
reaction. and the sequences of all these primers are as previously
reported (Varley' et al. 19981.
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RESULTS AND DISCUSSION
Screening ofthe TP53 gene detected a point mutation at the splice
acceptor site of intron 3 in both V-3 and his mother. but not in his
father. The mutation affects one of the invariant residues at the
splice acceptor site (agfTC -e aa/TC). and is predicted to perturb
splicing of intron 3. We have previously reported the mutation in
this family as part of a larger study of LFS families (Varley et al.
1997). but in the present report 'e have carried out more detailed
analysis of a larger number offamily members and determined the
effect of the mutation on splicing. To confirm that splicing 'a as
abnormal. we carried out RT-PCR analvsis on RNA extracted from
lymphocytes from the proband and his mother using primers
within exons 2/3 and 5 or 5/6. In addition to a fragment of the
expected size. two more products were seen (data not shown). one
approximatelv 20 bp smaller than the expected and the other
approximately 280 bp smaller. These products were gel purified
and sequenced directly. The smallest fragment corresponded to a
product in w'hich there was splicing bet'aeen the splice donor site
of intron 3 and the splice acceptor site of intron 4. generating a
product in which exon 4 A as completely- absent (Figure 2A). This
transcript is predicted to result in a protein product with an in-
frame deletion of codons 33-125. The transcript w-hich 'Aas 20 bp
smaller than normal A as the result ofaberrant splicing between the
splice donor of intron 3 and a cr'ptic splice acceptor site within
exon 4 (Figure 2B). The hypothetical protein product of this tran-
script would have an in-frame stop codon at the equivalent of posi-
tion 37. with four novel amino acids at the carboxv terminus. As
judged by the relative levels of each of the splice products in the
RT-PCR reaction. the wild-type allele was expressed at approxi-
mately the same level as the t'o aberrant products. however a-e
made no effort to cam, out quantitative analysis.
This mutation has not been reported as a germline mutation in
any other family. nor indeed has an identical mutation been
detected as a somatic event in a tumour. A surx e of the database
of TP53 mutations (Hollstein et al. 1996) found three intron 3
splice acceptor mutations. none of hich is identical to that
reported in this present study (Takahashi et al. 1990: Suzuki et al.
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Figure 1 Pedigree of family 86
1992: Lai et al. 1993) but all of which result in skipping of exon 4.
None of these mutations. however. results in the use of the cryptic
splice site reported in family 86. The cryptic splice site shows
good homology with the consensus splice acceptor sequence. and
its usage would result in the translation of a truncated TP53
product with an altered C-terminus. Both this product and the
product of the exon 4-skipped transcript would be predicted to be
non-functional.
DNA samples were available from a number of other family
members. all ofwhom were negative for the splice acceptor muta-
tion except for one individual with a meningeal sarcoma aged 29
(IV-9. see Fiaure 1). A number of cancer-affected individuals in
this family did not have the mutation. including 111-1 (ovanran
carcinoma aged 58). 111-16 (epidermoid carcinoma of the cervix
aged 43). IV-I (CIN III aged 36) and PV-3 (Wilms tumour aged 3).
This result is particularly interesting as previous studies have indi-
cated that WilmS tumours may occur at an increased frequency in
patients with Li-Fraumemn syndrome (Hartley et al. 1993). There
is only one report of a Wilms tumour patient with a germline
TP53 mutation (Bardeesy et al. 1994). in a family in which there
are two cases of Wilms tumour. However. in that family. the
Wilms tumour is unlikely to be due to the TP53 mutation because
the mutation was inherited from the mother. with the history of
Wilms tumour on the paternal side. The child's mother had a
strong personal history of cancer at a young age. includinc a
glioma. We have not detected a germline mutation in any
Li-Fraumeni syndrome family in which there is a Wilms tumour
(Varley et al. 1997) except the family described in this present
report. and the individual with Wilms was not a mutation carrier.
Although there is still evidence for a familial aggregation of
Wilms tumours and other tumours characteristic of LFS (Li et al.
1988: Hartley et al. 1993). it appears likely from our own studies.
including the present report. that this clustering is not due to the
presence of a germline TP53 mutation. The ages of onset and types
of tumours in II-1. I-16 and IV- I are not typical ofLFS. and we
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Figure 2 (A) A schemabc diagram showing exons 3. 4 and 5 of TP53 and
indicating the site of the splice acceptor mutation in intron 3. Two splice
products were detected by RT-PCR of polyA- RNA from V-3 and IV-5; one in
which there was splicing between the intron 3 donor and the intron 4
acceptor, and the second between Fe intron 3 donor and a cryptc splice
acceptor within exon 4. (B) The sequence of the splice acceptor site of intron
3 and the cryptic acceptor site in exon 4. The posibon of the splice sites are
indicated above the sequence, and the consensus splice acceptor sequence
is shown below for comparison
have confirmed that none of these tumours are associated with the
germline TP53 mutation. However. the presence ofthe mutation in
two affected individuals (IV-9 and V-3) confirms that the mutation
is causative of the cancer phenotype in this family. This type of
detailed study strongly reinforces the need to genotype as many
individuals as possible in such families to reach valid conclusions
about the spectrum of tumours related to inheritance of germline
TP53 mutations.
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Although the mutation reported in family 86 affects one of the
invariant residues ofthe splice acceptor sequence and is. therefore.
predicted to completely abolish correct splicing from the mutant
allele. we felt it necessary to demonstrate abnormal splicing before
offering the family a predictive test. Although we may have been
overcautious in this case. it is strongly recommended that novel
mutations. or those in which the functional significance is unclear.
are evaluated as fully as possible before being used in predictive
testing. The evaluation may take the form of testing in one of the
functional assays currently available or. in the case of splicing
mutations. analysis ofthe transcripts produced.
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